December 12, 2018 | English | عربي
Add to Twitter
 
Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
Eighty one percent overall response rate and 43% complete response rate observed in heavily pre-treated patients

Majority of patients evaluable for minimal residual disease achieved early, undetectable MRD